P1.01-106 Pembrolizumab Randomized, Phase 1 Study in Chinese Patients With Advanced NSCLC: KEYNOTE-032

Journal of Thoracic Oncology - United States
doi 10.1016/j.jtho.2018.08.663
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

P1.01-81 Phase 3 Study of Pemetrexed-Platinum With or Without Pembrolizumab for TKI-Resistant/EGFR-Mutated Advanced NSCLC: KEYNOTE-789

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-95 Crizotinib Treatment in 29 Advanced NSCLC Chinese Patients With ROS1 Rearrangement——A Single Chinese Cancer Institute Experience

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-09 Pembrolizumab Plus Ipilimumab or Placebo in 1L Metastatic NSCLC With PD-L1 Tumor Proportion Score (TPS) ≥50%: KEYNOTE-598

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Correction: Phase 2 Study of Pembrolizumab in Patients With Advanced Rare Cancers

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

P1.01-30 Crizotinib in Advanced Non-Adenocarcinoma, NSCLC (NA-NSCLC) Patients With ALK Rearrangement: A Retrospective Study and Literature Review

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-92 a Phase II Study of Afatinib Treatment for Elderly Patients With Previously Untreated Advanced NSCLC Harboring EGFR Mutations

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-33 Randomized Phase 2 Study Comparing CBDCA+PTX+BEV and CDDP+PEM+BEV in Treatment-Naïve Advanced Non-Sq NSCLC (CLEAR Study)

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

P1.01-40 Randomized Phase II Study of Docetaxel Plus Bevacizumab or Pemetrexed Plus Bevacizumab for Elderly PTS With Untreated Advanced NSCLC: TORG1323

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Randomized Phase II Study of the Bruton Tyrosine Kinase Inhibitor Acalabrutinib, Alone or With Pembrolizumab in Patients With Advanced Pancreatic Cancer

Journal for ImmunoTherapy of Cancer
OncologyMolecular MedicinePharmacologyCancer ResearchAllergyImmunology
2020English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy